Track topics on Twitter Track topics that are important to you
(MedPage Today) -- Several studies have shown that adding immune checkpoint inhibitors to chemotherapy is a superior approach to chemotherapy alone for treating patients with advanced or metastatic non-small cell lung cancer (NSCLC). Does that...
Original Article: Clinical Challenges: Immunotherapy and Chemo in NSCLCNEXT ARTICLE
GILOTRIF (afatinib) is a kinase inhibitor indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L8...